References: Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Treating Symptoms of Multiple Sclerosis Spasticity: Newest Evidence

111

Views

CrossRef citations to date

Altmetric

References

Kister I , BaconTE, ChamotEet al. Natural history of multiple sclerosis symptoms . Int. J. MS Care15 ( 3 ), 146 – 158 ( 2013 ).
PubMedGoogle Scholar
Flachenecker P , HenzeT, ZettlUK . Spasticity in patients with multiple sclerosis:clinical characteristics, treatment and quality of life . Acta Neurol. Scand.129 ( 3 ), 154 – 162 ( 2014 ).
PubMed Web of Science ®Google Scholar
Barnes M , KocerS, Murie FernandezMet al. An international survey of patients living with spasticity . Disabil. Rehabil.39 ( 14 ), 1428 – 1434 ( 2017 ).
PubMed Web of Science ®Google Scholar
Otero-Romero S , Sastre-GarrigaJ, ComiGet al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper . Mult. Scler.22 ( 11 ), 1386 – 1396 ( 2016 ).
PubMed Web of Science ®Google Scholar
SmPC Sativex® Oromucosal Spray ( 2018 ). www.medicines.org.uk/emc/product/602/smpc .
Google Scholar
Novotna A , MaresJ, RatcliffeSet al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis . Eur. J. Neurol.18 ( 9 ), 1122 – 1131 ( 2011 ).
PubMed Web of Science ®Google Scholar